Predicting the Probability that a Chemical Causes Steatosis Using Adverse Outcome Pathway Bayesian Networks (AOPBNs).


Journal

Risk analysis : an official publication of the Society for Risk Analysis
ISSN: 1539-6924
Titre abrégé: Risk Anal
Pays: United States
ID NLM: 8109978

Informations de publication

Date de publication:
03 2020
Historique:
received: 25 03 2019
revised: 17 10 2019
accepted: 19 10 2019
pubmed: 14 11 2019
medline: 14 10 2021
entrez: 14 11 2019
Statut: ppublish

Résumé

Adverse outcome pathway Bayesian networks (AOPBNs) are a promising avenue for developing predictive toxicology and risk assessment tools based on adverse outcome pathways (AOPs). Here, we describe a process for developing AOPBNs. AOPBNs use causal networks and Bayesian statistics to integrate evidence across key events. In this article, we use our AOPBN to predict the occurrence of steatosis under different chemical exposures. Since it is an expert-driven model, we use external data (i.e., data not used for modeling) from the literature to validate predictions of the AOPBN model. The AOPBN accurately predicts steatosis for the chemicals from our external data. In addition, we demonstrate how end users can utilize the model to simulate the confidence (based on posterior probability) associated with predicting steatosis. We demonstrate how the network topology impacts predictions across the AOPBN, and how the AOPBN helps us identify the most informative key events that should be monitored for predicting steatosis. We close with a discussion of how the model can be used to predict potential effects of mixtures and how to model susceptible populations (e.g., where a mutation or stressor may change the conditional probability tables in the AOPBN). Using this approach for developing expert AOPBNs will facilitate the prediction of chemical toxicity, facilitate the identification of assay batteries, and greatly improve chemical hazard screening strategies.

Identifiants

pubmed: 31721239
doi: 10.1111/risa.13423
pmc: PMC7397752
mid: NIHMS1594932
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

512-523

Subventions

Organisme : Intramural EPA
ID : EPA999999
Pays : United States

Informations de copyright

Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Références

Int J Biostat. 2010 Feb 26;6(2):Article 7
pubmed: 20305706
Biomed Res Int. 2015;2015:597134
pubmed: 26120584
J Lipid Res. 2003 May;44(5):978-85
pubmed: 12588952
Environ Health Perspect. 2016 Jul;124(7):910-9
pubmed: 26473631
Diabetes. 2011 May;60(5):1483-92
pubmed: 21464441
Mol Endocrinol. 2003 Feb;17(2):259-72
pubmed: 12554753
Semin Liver Dis. 2001;21(1):43-55
pubmed: 11296696
J Biol Chem. 2014 Feb 28;289(9):5510-7
pubmed: 24398675
Diabetes. 2008 Jul;57(7):1774-83
pubmed: 18586909
J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94
pubmed: 19812304
Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1333-9
pubmed: 11705737
PPAR Res. 2010;2010:
pubmed: 20936127
Mol Cell. 2000 Sep;6(3):517-26
pubmed: 11030332
J Biol Chem. 2007 Jul 13;282(28):20164-71
pubmed: 17522048
Regul Toxicol Pharmacol. 2017 Nov;90:185-196
pubmed: 28866267
Toxicol Sci. 2017 Sep 1;159(1):159-169
pubmed: 28903485
J Med Chem. 2001 Dec 20;44(26):4677-87
pubmed: 11741485
Mol Pharmacol. 1996 Nov;50(5):1157-66
pubmed: 8913347
Cell Metab. 2012 Oct 3;16(4):414-9
pubmed: 23000402
Curr Opin Lipidol. 2014 Jun;25(3):161-8
pubmed: 24751931
Antioxid Redox Signal. 2011 Oct 15;15(8):2135-46
pubmed: 21504366
J Biol Chem. 2009 May 29;284(22):15071-83
pubmed: 19366697
Mol Endocrinol. 2003 Jul;17(7):1255-67
pubmed: 12730332
Environ Toxicol Chem. 2010 Mar;29(3):730-41
pubmed: 20821501
Mol Cell Endocrinol. 2001 Jan 22;171(1-2):61-70
pubmed: 11165012
Am J Epidemiol. 2013 Jul 1;178(1):38-45
pubmed: 23703888
J Gastroenterol. 2013 Apr;48(4):434-41
pubmed: 23397118
Toxicol Sci. 2014 Dec;142(2):312-20
pubmed: 25466378
Mol Cell Endocrinol. 2001 May 15;176(1-2):49-56
pubmed: 11369442
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2323-8
pubmed: 11226238
J Endocrinol. 1998 Aug;158(2):237-46
pubmed: 9771468
J Appl Toxicol. 2016 Sep;36(9):1150-62
pubmed: 26851134
J Clin Invest. 2003 Sep;112(6):935-44
pubmed: 12975478
Crit Rev Biochem Mol Biol. 2010 Jun;45(3):199-214
pubmed: 20218765
Risk Anal. 2017 Feb;37(2):280-290
pubmed: 27088631
Gut. 2017 Jun;66(6):1154-1164
pubmed: 28341748
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
J Clin Invest. 2003 Mar;111(5):737-47
pubmed: 12618528

Auteurs

Lyle D Burgoon (LD)

US Army Engineer Research and Development Center, Vicksburg, MS, USA.

Michelle Angrish (M)

US Environmental Protection Agency, National Center for Environmental Assessment, Research Triangle Park, NC, USA.

Natalia Garcia-Reyero (N)

US Army Engineer Research and Development Center, Vicksburg, MS, USA.

Nathan Pollesch (N)

US Environmental Protection Agency, Mid-Continent Ecology Division, Duluth, MN, USA.

Anze Zupanic (A)

Eawag, Swiss Federal Institute for Aquatic Science and Technology, Dubendorf, Switzerland.

Edward Perkins (E)

US Army Engineer Research and Development Center, Vicksburg, MS, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH